Literature DB >> 30342249

Epidemiological investigation and successful management of a Burkholderia cepacia outbreak in a neurotrauma intensive care unit.

Neha Rastogi1, Surbhi Khurana2, Balaji Veeraraghavan3, Francis Yesurajan Inbanathan4, Suresh Kumar Rajamani Sekar5, Deepak Gupta6, Keshav Goyal7, Ashish Bindra8, Navdeep Sokhal9, Ashutosh Panda10, Rajesh Malhotra11, Purva Mathur12.   

Abstract

OBJECTIVE: The detailed epidemiological and molecular characterization of an outbreak of Burkholderia cepacia at a neurotrauma intensive care unit of a level 1 trauma centre is described. The stringent infection control interventions taken to successfully curb this outbreak are emphasized.
METHODS: The clinical and microbiological data for those patients who had more than one blood culture that grew B. cepacia were reviewed. Bacterial identification and antimicrobial susceptibility testing was done using automated Vitek 2 systems. Prospective surveillance, environmental sampling, and multilocus sequence typing (MLST) were performed for extensive source tracking. Intensive infection control measures were taken to further control the hospital spread.
RESULTS: Out of a total 48 patients with B. cepacia bacteraemia, 15 (31%) had central line-associated blood stream infections. Two hundred and thirty-one environmental samples were collected and screened, and only two water samples grew B. cepacia with similar phenotypic characteristics. The clinical strains characterized by MLST typing were clonal. However, isolates from the water represented a novel strain type (ST-1289). Intensive terminal cleaning, disinfection of the water supply, and the augmentation of infection control activities were done to curb the outbreak. A subsequent reduction in bacteraemia cases was observed.
CONCLUSION: Early diagnosis and appropriate therapy, along with the rigorous implementation of essential hospital infection control practices is required for successful containment of this pathogen and to curb such an outbreak.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Burkholderia cepacia; MLST typing; Neurotrauma unit; Novel ST type; Outbreak

Mesh:

Year:  2018        PMID: 30342249     DOI: 10.1016/j.ijid.2018.10.008

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  5 in total

1.  An intermittent outbreak of Burkholderia cepacia contaminating hematopoietic stem cells resulting in infusate-related blood stream infections.

Authors:  Anis Raddaoui; Farah Ben Tanfous; Yosra Chebbi; Aymen Mabrouk; Wafa Achour
Journal:  J Infect Prev       Date:  2022-02-08

Review 2.  Burkholderia cepacia Complex Bacteria: a Feared Contamination Risk in Water-Based Pharmaceutical Products.

Authors:  Mariana Tavares; Mariya Kozak; Alexandra Balola; Isabel Sá-Correia
Journal:  Clin Microbiol Rev       Date:  2020-04-15       Impact factor: 26.132

3.  Combined Clinical, Epidemiological, and Genome-Based Analysis Identified a Nationwide Outbreak of Burkholderia cepacia Complex Infections Caused by Contaminated Mouthwash Solutions.

Authors:  Jennifer K Bender; Sebastian Haller; Yvonne Pfeifer; Michael Hogardt; Klaus-Peter Hunfeld; Andrea Thürmer; Arina Zanuzdana; Markus Werner; Bernd Kunz; David Eisenberger; Niels Pfennigwerth; Volkhard A J Kempf; Guido Werner; Tim Eckmanns
Journal:  Open Forum Infect Dis       Date:  2022-03-09       Impact factor: 3.835

4.  Investigation of Burkholderia cepacia complex bacteremia outbreak in a neonatal intensive care unit: a case series.

Authors:  Tanisha Bharara; Anita Chakravarti; Mukesh Sharma; Priti Agarwal
Journal:  J Med Case Rep       Date:  2020-06-23

5.  Investigation and control of an outbreak of urinary tract infections caused by Burkholderia cepacian-contaminated anesthetic gel.

Authors:  Mingmei Du; Linjian Song; Yan Wang; Jijiang Suo; Yanling Bai; Yubin Xing; Lijun Xie; Bowei Liu; Lu Li; Yanping Luo; Yunxi Liu
Journal:  Antimicrob Resist Infect Control       Date:  2021-01-06       Impact factor: 4.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.